Oncology Ablation Market Report 2026

The oncology ablation market size has grown rapidly in recent years. It will grow from $1.45 billion in 2025 to $1.64 billion in 2026 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to rising prevalence of liver, kidney, and lung cancers, increasing demand for minimally invasive treatments, growing availability of advanced imaging technologies, expansion of hospitals and specialty oncology centers, increasing awareness of ablation as an alternative to surgery.

The oncology ablation market size is expected to see rapid growth in the next few years. It will grow to $2.61 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to growth in targeted and personalized ablation therapies, increasing adoption of percutaneous and laparoscopic ablation techniques, technological advancements in ablation equipment, expansion of oncology centers in emerging regions, rising integration of digital patient management and monitoring systems. Major trends in the forecast period include rising adoption of digital platforms for oncology ablation procedure management, increasing integration of ai and machine learning in tumor diagnosis and planning, growing implementation of precision medicine and genomic profiling for ablation therapy, rising automation in ablation devices and surgical equipment, increasing iot-enabled monitoring of ablation devices and patient outcomes.

The rising number of cancer diagnoses is expected to drive the growth of the oncology ablation market in the coming years. Cancer diagnosis involves identifying and confirming the presence of cancer through medical tests, imaging studies, and pathological examination of tissue samples. The increase in cancer diagnoses is attributed to factors such as aging populations, improved screening programs, greater awareness leading to earlier detection, and environmental influences. Oncology ablation provides minimally invasive treatment options for tumors detected through these diagnoses, enabling precise destruction of tumors and improving patient outcomes. For example, in May 2024, the National Cancer Institute, the US federal government’s principal agency for cancer research and training, projected approximately 2,001,140 new cancer cases in the United States, with prostate, lung, and colorectal cancers accounting for roughly 48% of all male diagnoses. By 2040, the annual number of new cancer cases is expected to rise to 29.9 million, indicating a substantial future increase in cancer incidence. Additionally, in June 2022, the American Cancer Society, a US-based non-profit cancer awareness organization, reported about 1.9 million new cancer cases diagnosed in the USA. Consequently, the growing number of cancer diagnoses is fueling the expansion of the oncology ablation market.

Leading companies in the oncology ablation market are focusing on the development of advanced technologies, including precise ablation systems, integrated imaging solutions for real-time guidance, and enhanced safety features. Advanced ablation systems with improved precision are medical devices designed to accurately target and eliminate abnormal tissue, such as tumors, while minimizing damage to surrounding healthy tissue. For instance, in March 2024, Medtronic Plc, an Ireland-based medical equipment manufacturer, received US Food and Drug Administration approval for the OsteoCool 2 bone tumor ablation system, intended to treat painful bone metastases and benign tumors like osteoid osteoma. This upgraded system includes significant enhancements, such as the capability to operate four internally cooled probes simultaneously, allowing for ablation of two vertebral bodies at once or the creation of larger ablation zones in non-spinal applications.

In February 2024, AngioDynamics, a US-based manufacturer of oncology ablation devices, formed a strategic partnership with Immunophotonics, Inc., to combine AngioDynamics’ ablation devices with Immunophotonics’ lead immunotherapy asset, IP-001, for the treatment of solid tumors. Through this collaboration, both companies aim to advance interventional immuno-oncology by leveraging the synergistic potential of combining ablation and immunotherapy in clinical practice. Immunophotonics, Inc. is a US-based biotechnology company specializing in the development of innovative immunotherapy solutions for solid tumor cancers.

Major companies operating in the oncology ablation market are Medtronic plc, Boston Scientific Corporation, AngioDynamics Inc, EDAP TMS S.A., Merit Medical Systems Inc, Misonix Inc, BSD Medical Corporation, Sonacare Medical, Chongqing Haifu Medical Technology Co Ltd, HealthTronics Inc, Galil Medical Inc, SonaCare Medical LLC, BVM Medical Ltd, BTG International Ltd, Mermaid Medical, HistoSonics Inc, Medigus Ltd, Miramar Labs Inc, KLS Martin Group, Endocare Inc, InnovaCore Inc, IceCure Medical Inc, RF Medical Co Ltd, CSA Medical Inc.

North America was the largest region in the oncology ablation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology ablation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oncology ablation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the oncology ablation market by increasing costs of importing high-precision ablation devices, imaging systems, and surgical instruments, affecting hospitals, specialty clinics, and diagnostic centers primarily in north america, europe, and asia-pacific. While tariffs increase operational expenses, they also encourage local manufacturing, sourcing diversification, and domestic investment in oncology equipment, which may strengthen supply chains and reduce dependency on imports.

The oncology ablation market research report is one of a series of new reports that provides oncology ablation market statistics, including oncology ablation industry global market size, regional shares, competitors with a oncology ablation market share, detailed oncology ablation market segments, market trends and opportunities, and any further data you may need to thrive in the oncology ablation industry. This oncology ablation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oncology ablation is a minimally invasive procedure designed to destroy cancerous tumors by applying extreme conditions directly to the tumor tissue. This method aims to reduce or eliminate tumors while preserving the surrounding healthy tissue.

The primary technologies used in oncology ablation include radiofrequency ablation, microwave ablation, cryoablation, and irreversible electroporation ablation. Radiofrequency ablation is a medical technique that uses radiofrequency energy to produce heat and destroy abnormal tissue or nerve pathways. Treatment methods include surgical ablation, laparoscopic ablation, and percutaneous ablation. This technology is employed in the treatment of cancers such as kidney cancer, liver cancer, breast cancer, lung cancer, and prostate cancer.

The oncology ablation market consists of revenues earned by entities by providing services such as tumor removal, reduction, and management of metastatic cancer lesions. The market value includes the value of related goods sold by the service provider or included within the service offering. The oncology ablation market also includes sales of high-intensity focused ultrasound (HIFU) devices, laser ablation devices, and electromagnetic ablation devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.